Howe Aaron S, Leung Tiffany, Bani-Fatemi Ali, Souza Renan, Tampakeras Maria, Zai Clement, Kennedy James L, Strauss John, De Luca Vincenzo
aGroup for Suicide Studies, CAMH bNeurogenetics, Centre for Addiction and Mental Health, Toronto, Ontario, Canada cDepartment of General Biology, Federal University of Minas Gerais, Belo Horizonte, Minas Gerais, Brazil.
Psychiatr Genet. 2014 Jun;24(3):110-5. doi: 10.1097/YPG.0000000000000031.
OBJECTIVE(S): In the present study, we examined whether there was an association between dopamine-β hydroxylase (DBH) promoter polymorphisms (a 5'-ins/del and a GTn repeats) and a history of suicide attempt in 223 chronic schizophrenia individuals using statistical and molecular analyses. Within the genetic association study design, we compared the statistical haplotype phase with the molecular phase produced by the amplicon size analysis.
The two DBH polymorphisms were analysed using the Applied Biosystem 3130 and the statistical analyses were carried out using UNPHASED v.3.1.5 and PHASE v.2.1.1 to determine the haplotype frequencies and infer the phase in each patient. Then, DBH polymorphisms were incorporated into the Haploscore analysis to test the association with a history of suicide attempt.
In our sample, 62 individuals had a history of suicide attempt. There was no association between DBH polymorphisms and a history of suicide attempt across the different analytical strategies applied. There was no significant difference between the haplotype frequencies produced by the amplicon size analysis and statistical analytical strategies. However, some of the haplotype pairs inferred in the PHASE analysis were inconsistent with the molecular haplotype size measured by the ABI 3130.
The amplicon size analysis proved to be the most accurate method using the haplotype as a possible genetic marker for future testing. Although the results were not significant, further molecular analyses of the DBH gene and other candidate genes can clarify the utility of the molecular phase in psychiatric genetics and personalized medicine.
在本研究中,我们运用统计分析和分子分析方法,对223例慢性精神分裂症患者进行研究,以检验多巴胺-β羟化酶(DBH)启动子多态性(一个5'-插入/缺失和一个GTn重复序列)与自杀未遂史之间是否存在关联。在基因关联研究设计中,我们将统计单倍型相位与扩增子大小分析产生的分子相位进行了比较。
使用Applied Biosystem 3130对两种DBH多态性进行分析,并使用UNPHASED v.3.1.5和PHASE v.2.1.1进行统计分析,以确定单倍型频率并推断每位患者的相位。然后,将DBH多态性纳入Haploscore分析,以检验与自杀未遂史的关联。
在我们的样本中,有62例患者有自杀未遂史。在所应用的不同分析策略中,DBH多态性与自杀未遂史之间均无关联。扩增子大小分析产生的单倍型频率与统计分析策略之间无显著差异。然而,PHASE分析中推断的一些单倍型对与ABI 3130测量的分子单倍型大小不一致。
扩增子大小分析被证明是使用单倍型作为未来检测可能的遗传标记的最准确方法。尽管结果不显著,但对DBH基因和其他候选基因进行进一步的分子分析可以阐明分子相位在精神科遗传学和个性化医疗中的效用。